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Abstract
This observational study aimed to investigate whether the reported association between family history (FH) of breast cancer
(BC) or ovarian cancer (OC) and OC risks in BRCA1/2 mutation carriers can be explained by mutation position on the gene.
In total, 3310 female BRCA1/2 mutation carriers participating in a nationwide prospective cohort (Hereditary Breast and
Ovarian Cancer in the Netherlands) were included. FH was classified according to cancer occurrence in first-degree relatives
(BC only, OC only, both, neither) and mutations were classified according to their position on the gene (OC cluster region
(OCCR), BC cluster region, neither). The main outcome was OC occurrence. Cox proportional-hazard models were applied
to investigate the association between FH and OC risks before and after adjusting for mutation position. Of all women
included, 202 were diagnosed with OC. A BC-only FH tended to be associated with lower OC risks when compared with a
FH without BC/OC (HR: 0.79, 95% CI: 0.52–1.17; HR: 0.59, 95% CI: 0.33–1.07 for BRCA1 and BRCA2, respectively)
while an OC-only FH tended to be associated with higher risks (HR: 1.58, 95% CI: 0.90–2.77; HR: 1.75, 95% CI: 0.70–4.37
for BRCA1 and BRCA2, respectively). After adjusting for mutation position, association between FH and OC risks was
slightly smaller in magnitude (HR: 0.85, 95% CI: 0.55–1.30; HR: 0.64, 95% CI: 0.34–1.21 for BC-only FH in BRCA1 and
BRCA2, respectively; HR: 1.46, 95% CI: 0.80–2.68; HR: 1.49, 95% CI: 0.44–4.02 for OC-only FH in BRCA1 and BRCA2,
respectively), indicating that mutation position explains only part of the association. Considering the magnitude of the
observed trend, we do not believe FH should be used to change counseling regarding OC prevention.
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Ovarian cancer (OC) is the seventh most prevalent cancer in
women worldwide [1]. Up to 24% of OC cases are due to a
genetic predisposition, most often associated with BRCA1/2
mutations [2]. Numerous studies aimed at estimating the
lifetime OC risk for BRCA1/2 mutation carriers [3–5]
obtaining varying results according to the population stu-
died and methodology applied [6], with estimates ranging
between 31–59% in BRCA1 and 6–18% in BRCA2 mutation
carriers [3–5]. Subsequent studies aimed to identify genetic
and environmental factors associated with the observed risk
variation in mutation carriers [7].
A family history (FH) of OC (hereafter: OCFH) has been
reported to be a predictor of OC risk, with increased risks
observed among relatives of OC patients in the general
population (relative risks: 2.4–24.0) [8–11]. Subsequently,
it was observed that also among BRCA1 mutation carriers,
those with an OCFH had increased OC risks relative to
those with no OCFH, whereas a FH of breast cancer (BC;
hereafter BCFH) lowered OC risks [12]. This suggested
that, besides the mere presence of a BRCA1/2 mutation,
other factors might influence OC risk.
Shortly after BRCA1/2 were described, a possible
genotype–phenotype correlation was reported [13, 14].
Mutations in central regions of BRCA1 and BRCA2
appeared to be associated with a higher incidence of OC,
relative to BC incidence [15, 16]. These regions of BRCA1/
2 were named “ovarian cancer cluster regions” (OCCR). The
reported observations were recently confirmed in a large
international study, which not only confirmed the pre-
viously described OCCRs (defining its’ boundaries more
precisely), but also identified multiple breast cancer cluster
regions (BCCRs). However, the study did not account for
the contribution of BCFH or OCFH [17]. It remains unclear
to what extent the variation in OC risks in BRCA1/2
mutation carriers is explained by mutation position, by
OCFH or BCFH, or by an interaction of these variables.
In a previous study, we investigated the combined impact
of BCFH or OCFH and mutation position on OC risks in
women from BRCA1/2 families. OCFH was associated with
increased OC risks in BRCA1 families, however, this
association was no longer significant after taking mutation
position into account. For women from BRCA2 families,
OCFH was a predictor of OC risk independent from the
mutation position [18]. The study included Dutch women
from a small geographical area (which was reflected by a
limited mutation spectrum) and used the initial definition of
the OCCRs [15, 16], which is less precise than the recently
proposed definition of OCCRs and BCCRs [17].
Because of their increased OC risk, BRCA1/2 mutation
carriers are advised to have risk-reducing salpingo-oophor-
ectomy (RRSO) before the age at which OC risk starts to
rise, regardless of their FH or mutation position [19]. RRSO
induces early menopause, which has several unwanted
consequences [20]. Understanding the causes for variation
on age-related OC risk among the group of BRCA1/2
mutation carriers who are aware of their mutation and seek
counseling could enable individualized risk estimations,
which could have implications for patient counseling on
timing of RRSO. The present study aimed to investigate in a
national Dutch cohort of female BRCA1/2 mutation carriers
whether the association between cancer FH and OC risks
can be explained by the mutation position on the gene.
Patients and methods
Study population
The Dutch Hereditary Breast and Ovarian Cancer study
(HEBON) [21] prospectively includes subjects tested for a
genetic predisposition of BC/OC with retrospective data
collection and prospective follow-up. From 1999 onward,
individuals undergoing genetic testing for BRCA1/2 muta-
tions at one of the nine genetic centers in the Netherlands
were invited to participate in this study. All participants
were asked to fill out a questionnaire, covering information
on date of birth, medical history (including personal history
of OC), previous surgeries, and FH of cancer. Data
regarding DNA testing were provided by the clinics and is
constantly updated during follow-up, as is information on
survival. The study was approved by the ethics committees
of all participating centers and all patients enrolled provided
written informed consent.
For the present study, we selected from the HEBON
database proven female carriers of a BRCA1 or BRCA2
mutation. Participants replied to the study questionnaire
between February 1999 and November 2013. Information
on OC occurrence in the included patients was cross-
checked with the Nationwide Network and Registry of
Histo- and Cytopathology in the Netherlands (last updated
in August 2014) [22] for confirmation of self-reported cases
and identification of cases diagnosed after patients filled out
the questionnaires. Women who had both a BRCA1 and a
BRCA2 mutation (n= 14), deletions involving several
domains of BRCA1/2 (n= 11), or of whom follow-up time
could not be calculated because of missing information on
age at OC diagnosis (n= 0), age at RRSO (n= 28), or
filling out the questionnaire (n= 20) were excluded.
Data processing
Follow-up time was calculated from date of birth until date
of censoring event, which could be diagnosis of OC, RRSO,
or death; whichever occurred first. Women in whom no
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censoring events occurred were censored at date of com-
pletion of the questionnaire. Women were considered to
have had RRSO when they reported surgical removal of
both ovaries, regardless of whether the ovaries were
removed at the same or at different time points. When
ovaries were removed at different time points, women were
censored at the time of second oophorectomy. The number
of women-years at risk was computed for each study par-
ticipant from age 18 until censoring.
Occurrence of BC and OC in the family, as reported in
the questionnaire, was recorded for each first-degree female
relative (FDR). Cancer FH in FDR was initially classified in
four categories: no BC or OC, BC cases only, OC cases
only, or both BC and OC cases. To further investigate the
effect of FH on OC risks, families were subsequently
classified in two other ways: families with BC cases in
FDRs vs. families without BC cases in FDRs (regardless of
the occurrence of OC), and families with OC cases in FDRs
vs. families without OC cases in FDRs (regardless of the
occurrence of BC).
Mutation position was classified based on the recent
publication by Rebbeck et al. [17], which proposed a
classification based on the creation of several bins of
mutations according to base-pair location across BRCA1
and BRCA2. Bins with significant differences in the ratio of
BC vs. OC hazard ratios (RHR) were considered to be
BCCR or OCCR. In this way, in the BRCA1 gene BCCR1
(nucleotides 179–505), OCCR (nucleotides 1380–4064),
BCCR2 (nucleotides 4328–4945), and BCCR2’ (nucleo-
tides 5261–5563) were defined, as well as BCCR1
(nucleotides 0–596), BCCR1’ (nucleotides 772–1806),
OCCR1 (nucleotides 3249–5681 and 5946), OCCR2
(nucleotides 6645–7471), and BCCR2 (nucleotides
7934–8904) in the BRCA2 gene. Due to the relatively small
number of participants in our study as compared with the
Rebbeck paper, for the sake of this analysis, we classified
mutations in three categories only: OCCR, BCCR, or nei-
ther OCCR nor BCCR. When there were two BCCR
regions in a segment of the gene, interrupted by a segment
with nonsignificant differences in RHR, this “in between”
segment was considered as part of that BCCR region. The
same applied for OCCR. In this way in each BRCA gene,
we have only one BCCR in the 5’ end and one in the 3’ end,
and one OCCR in the center. All mutations, including fra-
meshift mutations, were classified according to their base-
pair location in the gene.
Data analysis
Characteristics of study participants, frequency of OC, types
of FH, and mutation position were described separately for
women with BRCA1 and BRCA2 mutations. T-tests and chi-
square tests were applied to compare BRCA1 and BRCA2
mutation carriers regarding these characteristics. The out-
come measure of this study was the occurrence of OC. The
number of OC cases per 1000 women-years at risk was
described for different age groups according to each cate-
gory of FH and of mutation position.
The impact of BCFH and OCFH on the age-related
penetrance of OC was assessed with univariate Cox
proportional-hazard models, and so was the impact of
mutation position. Subsequently, multivariable Cox
proportional-hazard models were applied to investigate the
association between each of the proposed classifications of
FH and OC risk adjusted for the mutation position. To
explore the effect of birth cohorts (classified as birth before
1940 vs. birth in 1940 or later) and of a personal history of
BC (and in this way a possible protective effect of previous
chemotherapy on OC risk) on the association between FH
and OC risk, these factors were also added to the models.
The assumption of proportionality was checked by assess-
ment of log minus log plots. Results were expressed as
hazard ratios (HRs) with 95% confidence intervals (95%
CIs).
To assess the risk of bias, three sensitivity analyses were
performed. Because no data imputation method was
applied, in the main analyses only women with complete
information on the factor(s) assessed in each model were
considered in that specific model. In sensitivity analysis 1,
women with incomplete information on FH or mutation
position were excluded. Because patients are often referred
for genetic testing because of an OC diagnosis, OC risks
might be overestimated due to ascertainment/referral bias.
In sensitivity analysis 2, women diagnosed with OC before
testing positive for a BRCA1/2 mutation were excluded.
Finally, because information regarding cancer FH was
derived through questionnaires, which were filled out dur-
ing a different time frame than data regarding cancer
occurrence was retrieved from the national pathology
database, FH at the time of cancer diagnosis could be out-
dated, which could lead to misclassification bias. On sen-
sitivity analysis 3, women who filled out the study
questionnaire >1 year before being diagnosed with OC
were excluded. All tests performed previously were repe-
ated in these subsets of patients. OC incidence per 1000
women-years at risk and the respective 95% CIs were
estimated in R-Studio Version 0.98.1091 [23]. All other
statistical analyses were performed with IBM SPSS version
20.0 (IBM Corp., NY, USA). All tests were two-sided and
p-values< 0.05 were considered significant.
Results
A total of 3383 BRCA1/2 mutation carriers were identified.
Fourteen women were excluded for having both a BRCA1
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and BRCA2 mutation, 11 for having a large deletion and 48
for missing information on follow-up time. In total 3310
mutation carriers (2147 BRCA1 and 1163 BRCA2) were
included in the analysis (Fig. 1), among whom 202 cases of
OC were diagnosed (195 self-reported cases and 7 addi-
tional cases identified through the national pathology data-
base; of self-reported cases 93.8% were confirmed by
pathology). The mean age at OC diagnosis among BRCA1
mutation carriers was 52.0 years (SD: 9.4), which was not
significantly different from the mean age at diagnosis in
BRCA2 mutation carriers (53.5 years; SD: 10.2). Of all
women included, 1 867 had undergone a RRSO at a mean
age of 45.7 (SD: 8.7) in BRCA1 and 48.9 (SD: 9.1) in
BRCA2 mutation carriers (Table 1).
The incidence of OC per 1000 women-years at risk was
overall higher in women with only OCFH (i.e., no BCFH)
than in women with only BCFH (i.e., no OCFH) in all age
groups, although CIs were wide and overlapping. Regarding
mutation position, in most age groups OC was more fre-
quent in women with OCCR mutations than in women with
BCCR mutations (Table 2), which is in agreement with
previous findings.
Univariate analyses indicated that OC risk in BRCA1 and
BRCA2 mutation carriers tended to be affected by the type
of FH. A FH with BC cases only tended to be associated
with lower OC risks when compared with a FH without BC
or OC cases (HR: 0.79 95% CI: 0.52–1.17 for BRCA1 and
HR: 0.59, 95% CI: 0.33–1.07 for BRCA2 mutation carriers).
Fig. 1 Flowchart of patient
selection
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On the contrary, a FH with OC cases only tended to be
associated with higher OC risks than a FH with no BC or
OC (HR: 1.58, 95% CI: 0.90–2.77 for BRCA1 and HR:
1.75, 95% CI: 0.70–4.37 for BRCA2 mutation carriers). The
univariate analyses also revealed that overall, mutation
position tended to be associated with OC risks for BRCA2
(HR: 1.67, 95% CI: 0.77–3.62 for OCCR and HR: 0.45,
95% CI: 0.14–1.51 for BCCR, mutations outside OCCR/
BCCR as reference, p-value: 0.03 in the univariate model),
but not BRCA1 mutation carriers (HR: 1.28, 95% CI:
0.76–2.15 for OCCR and HR: 1.09, 95% CI: 0.65–1.82 for
BCCR, mutations outside OCCR/BCCR as reference,
p-value: 0.58 in the univariate model; Table 3).
In the multivariate analyses including FH and mutation
position, the impact of a BC-only and of an OC-only FH onOC
risks when compared with a FH without BC or OC presented
comparablemagnitude,with changes inHR ranging from0% to
30% when compared with the univariate models (HR: 0.85,
95%CI: 0.55–1.30 and HR: 0.64, 95%CI: 0.34–1.21 for a BC-
only FH in BRCA1 and BRCA2mutation carriers, respectively;
HR: 1.46, 95%CI: 0.80–2.68 andHR: 1.49, 95%CI: 0.55–4.02
for an OC-only FH in BRCA1 and BRCA2 mutation carriers,
respectively; Table 3), although after taking mutation position
into account neither of the models were significant. In com-
parison with the univariate model including mutation position
only, adding information on FH to the models significantly
improved model fit for BRCA1 (p< 0.001) but not for BRCA2
mutation carriers (p= 0.06). Multivariate models including
information not only on FH and mutation position, but also on
birth cohorts and a personal history of BC yielded comparable
results, with changes in HR mostly lower than 10% (Supple-
mentary Table 1).
Sensitivity analyses 1 (excluding women with missing
information) and 3 (excluding women who replied to the
Table 1 Female carriers’ characteristics
BRCA1 BRCA2 p-Value Total
Mutation carriers 2147 1163 – 3310
Mean age at questionnaire in years (SD) 47.1 (12.9) 49.3 (12.8) <0.01 47.8 (12.9)
Mean follow-up time in years (SD)a 43.8 (11.7) 46.4 (11.9) <0.01 44.7 (11.8)
N of OC cases (%) 149 (6.9%) 53 (4.6%) <0.01 202 (6.1%)
Mean age at OC in years (SD) 52.0 (9.4) 53.5 (10.2) 0.34 52.4 (9.6)
N of women who had RRSO (%) 1195 (55.7%) 672 (57.8%) 0.44 1867 (56.4%)
Mean age at RRSO in years (SD) 45.7 (8.7) 48.9 (9.1) <0.001 46.8 (8.9)
Median N of affected FDRs (range)
N of relatives affected with BC 0.85
0 857 (44.2%) 485 (43.9%) 1342 (44.1%)
1 807 (41.6%) 459 (41.5%) 1266 (41.6%)
2 214 (11.0%) 121 (11.0%) 335 (11.0%)
3 54 (2.8%) 32 (2.9%) 86 (2.8%)
4 8 (0.4%) 8 (0.7%) 16 (0.5%)
N of relatives affected with OC <0.01
0 1444 (76.2%) 947 (87.4%) 2391 (80.2%)
1 403 (21.3%) 127 (11.7%) 530 (17.8%)
2 42 (2.2) 10 (0.9%) 57 (1.7%)
3 7 (0.4%) 0 (0.0%) 7 (0.2%)
Type of FH of cancer in FDRs (N, %) <0.01
OC only 242 (12.7%) 81 (7.4%) 323 (10.8%)
BC only 967 (50.9%) 600 (55.0%) 1567 (52.4%)
OC and BC 113 (6.0%) 18 (1.7%) 131 (4.4%)
No OC or BC 577 (30.4%) 391 (35.9%) 968 (32.4%)
Mutation position on the gene (N, %) <0.01
OCCR 671 (35.7%) 563 (52.6%) 1234 (41.9%)
BCCR 857 (45.7%) 287 (26.8%) 1144 (38.8%)
Outside OCCR/BCCR 349 (18.6%) 221 (20.6%) 570 (19.3%)
SD standard deviation, OC ovarian cancer, RRSO risk-reducing salpingo-oophorectomy, FH family history, FDR first-degree relative, BC breast
cancer, OCCR ovarian cancer cluster region, BCCR breast cancer cluster region
a Follow-up time was calculated from date of birth until censoring event, which could be OC diagnosis, RRSO, or death
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Table 2 Cancer incidence per 1000 women-years of follow-up for different age groups according to family history of cancer and mutation position
on the gene
BRCA1 BRCA2
Family history of cancer
Age
group





18–30 No BC or OC 1 6742 0.15 (0.04–0.83) 1 4581 0.22 (0.06–1.22)
BC 0 11212 – 1 7063 0.14 (0.04–0.79)
OC 1 2837 0.35 (0.09–1.96) 0 971 –
Both 0 1341 – 0 212 –
30–40 No BC or OC 4 4457 0.90 (0.24–2.30) 3 3119 0.96 (0.20–2.81)
BC 5 7544 0.66 (0.21–1.55) 1 5152 0.19 (0.05–1.08)
OC 2 1921 1.04 (0.13–3.76) 0 724 –
Both 0 981 – 0 163 –
40–50 No BC or OC 10 2306 4.34 (2.08–7.98) 6 1777 3.38 (1.24–7.35)
BC 20 4332 4.62 (2.82–7.13) 2 3363 0.59 (0.07–2.15)
OC 5 859 5.82 (1.89–13.58) 2 412 4.85 (0.59–17.54)
Both 0 595 – 0 97 –
50–60 No BC or OC 16 933 17.14 (9.80–27.85) 6 874 6.86 (2.52–14.94)
BC 22 1819 12.09 (7.58–18.31) 11 1545 7.12 (3.55–12.74)
OC 6 260 23.081
(8.47–50.83)
3 152 19.74 (4.07–57.68)
Both 5 318 15.72 (5.11–36.69) 0 50 –
>60 No BC or OC 8 245 32.65
(14.10–64.34)
5 250 20.00 (6.49–46.67)
BC 10 513 19.49 (9.35–35.85) 8 504 15.87 (6.85–31.28)




Both 2 122 16.39 (1.99–59.22) 1 7 142.86
(3.61–795.95)











18–30 None 0 3998 – 0 2609 –
OCCR 1 7784 0.13 (0.03–0.72) 1 6570 0.15 (0.04–0.85)
BCCR 1 9955 0.10 (0.03–0.56) 0 3374 –
30–40 None 0 2645 – 2 1839 1.09 (0.13–3.93)
OCCR 5 5088 0.98 (0.32–2.29) 2 4644 0.43 (0.05–1.56)
BCCR 7 6611 1.06 (0.43–2.18) 0 2350 –
40–50 None 6 1444 4.16 (1.52–9.04) 1 1106 0.90 (0.02–5.04)
OCCR 18 2609 6.90 (4.09–10.90) 8 2856 2.80(1.21–5.52)
BCCR 16 3485 4.59 (2.62–7.46) 0 1406 –
50–60 None 12 534 22.47
(11.61–39.25)
0 528 –
OCCR 10 996 10.04 (4.81–18.46) 14 1245 11.24 (6.15–18.87)
BCCR 23 1455 15.81
(10.02–23.72)
2 674 2.97 (0.36–10.71)
>60 None 2 141 14.18
(17.18–51.24)
5 168 29.76 (9.66–69.45)
OCCR 14 302 7 394 17.77 (7.14–36.61)
The association between cancer family history and ovarian cancer... 853
questionnaire >1 year before being diagnosed with OC)
yielded results comparable to the main analyses. In sensi-
tivity analyses 2 (excluding women diagnosed with OC
before testing positive for a BRCA1/2 mutation), the
direction of the associations observed was overall similar to
the main analyses. However, due to small numbers, results
were not significant (Supplementary Tables 2, 3 and 4).
Discussion
In this multicenter study including 3310 women with a
BRCA1 or BRCA2 mutation, we observed that, when
compared with FH without BC or OC cases, a BC-only FH
among FDRs tended to be associated with lower OC risks
(HR: 0.79, 95% CI: 0.52–1.17 for BRCA1 and HR: 0.59,
95% CI: 0.33–1.07 for BRCA2), whereas a FH with OC
cases only tended to be associated with higher OC risks
(HR: 1.58, 95% CI: 0.90–2.77 for BRCA1 and HR: 1.75,
95% CI: 0.70–4.37 for BRCA2). After taking information
on mutation position into account, the association between
FH and OC risks presented comparable magnitude (HR:
0.85, 95% CI: 0.55–1.30 and HR: 0.64, 95% CI: 0.34–1.21
for a FH of BC only among BRCA1 and BRCA2 mutation
carriers, respectively; HR: 1.46, 95% CI: 0.80–2.68 and
HR: 1.49, 95% CI: 0.55–4.02 for a FH of OC only among
BRCA1 and BRCA2 mutation carriers, respectively). This
indicates that the position of the mutation in the gene in
three categories may explain part, but not all of the FH
impact on OC risks.
Our results are in line with a recent study reporting a
nonsignificant trend toward an increased risk of OC among
BRCA1/2 mutation carriers with a FH of OC compared with
those without a FH of the disease (HR: 1.24, 95% CI:
0.75–2.03 for BRCA1 and HR: 1.26 95% CI: 0.43–3.69 for
BRCA2 women with one affected relative) [24]. Further-
more, the magnitude of the impact of a BCFH on OC risks
in BRCA1/2 mutation carriers observed in the present ana-
lyses is comparable to a study by Metcalfe et al. They
reported a HR of 0.75 per affected first- or second-degree
relative (SDR) with BC, compared with no BCFH, among
BRCA1 mutation carriers, although the number of cases in
BRCA2 women was too low for analysis [12]. Our study
does not consider the number of affected relatives, however,
in the present study only 25% of women with BCFH and
6% of women with OCFH reported >1 relative with the
disease.
The results observed in this study partly contradict our
previous observation regarding the impact of type of cancer
FH on OC risks adjusted for mutation position [18]. We
previously reported that a FH with OC only (no BC) was
associated with increased OC risks when compared with
families with BC cases (regardless of the occurrence of OC)
independently from mutation position on the gene in
BRCA2 (HR: 4.48, 95% CI: 2.28–8.81), but not in BRCA1
mutation carriers [18]. This discrepancy may be due to
population and methodological differences between the two
studies. The previous study was smaller, contained on
average larger families, the information on FH of cancer
was acquired through the genetics file and included data on
FDRs and SDRs. For the present study, information on FH
was acquired for FDRs only (information for SDRs was not
available), through a self-administered questionnaire,
whereas self-reported information on the occurrence of OC
in the included patients was validated. Although self-
administered questionnaires may be associated with lower
accuracy and completeness of data, information for FDRs
tends to be more accurate than for SDRs [25]. Furthermore,
the discrepancy between the present and the previous study
may be due to differences in mutation spectrum. A list with
all the mutations identified in the current study and the
number of women with each specific mutation is provided
on supplementary file 1.
The magnitude of the positive correlation between
mutation position (OCCR, BCCR, or neither) and OC risk
observed in the present study (HR:1.28 for BRCA1-OCCR
mutations and HR:1.67 for BRCA2-OCCR mutations,
compared with mutations outside OCCR/BCCR) is in line
with a previous report using retrospective data [17].
Although a genotype–phenotype correlation in BRCA1/2
Table 2 (continued)
BRCA1 BRCA2
Family history of cancer
Age
group







BCCR 6 323 18.58 (6.82–40.43) 2 131 15.27 (1.85–55.15)
FH family history, OC number of ovarian cancer cases, Women-years number of women-years at risk, BC breast cancer, OCCR ovarian cancer
cluster region, BCCR breast cancer cluster region
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Table 3 The impact of family history of cancer and of mutation position on ovarian cancer risks in BRCA1/2 mutation carriers
BRCA1 BRCA2
OC cases/N HR 95%CI p-Value OC cases/N HR 95% CI p-Value
Univariate
Family history 0.03 0.08
No BC or OC 39/577 1.00 – 1.00 21/391 1.00 – 1.00
BC only 59/967 0.79 0.52–1.17 0.22 23/600 0.59 0.33–1.07 0.08
OC only 18/242 1.58 0.90–2.77 0.11 6/81 1.75 0.70–4.37 0.23
OC and BC 7/113 0.52 0.23–1.16 0.11 1/18 1.02 0.14–7.60 0.99
Family history
Without BC 57/819 1.00 – 1.00 27/472 1.00 – 1.00
With BC 66/1080 0.65 0.46–0.93 0.02 24/618 0.54 0.31–0.95 0.03
Family history
Without OC 98/1544 1.00 – 1.00 44/991 1.00 – 1.00
With OC 25/355 1.17 0.76–1.82 0.47 7/99 2.16 0.97–4.83 0.06
Mutation position 0.58 0.03
Outside OCCR/BCCR 20/349 1.00 – 1.00 8/221 1.00 – 1.00
OCCR 48/671 1.28 0.76–2.15 0.36 32/563 1.67 0.77–3.62 0.20
BCCR 54/857 1.09 0.65–1.82 0.75 4/287 0.45 0.14–1.51 0.20
Multivariatea
Model I
Family history 0.13 0.29
No BC or OC 37/543 1 – 1.00 19/373 1 – 1.00
BC only 50/839 0.85 0.55–1.30 0.44 19/547 0.64 0.34–1.21 0.17
OC only 15/214 1.46 0.80–2.68 0.22 5/75 1.49 0.55–4.02 0.43
OC and BC 6/94 0.52 0.22–1.23 0.14 1/17 1.34 0.17–10.28 0.78
Mutation position 0.43 0.04
Outside OCCR/BCCR 18/314 1 – 1.00 8/211 1 – 1.00
OCCR 46/608 1.27 0.74–2.20 0.39 32/526 1.66 0.75–3.64 0.21
BCCR 44/768 0.98 0.57–1.70 0.94 4/275 0.48 0.14–1.61 0.23
Model II
Family history
Without BC 52/757 1.00 – 1.00 24/448 1.00 – 1.00
With BC 56/933 0.72 0.49–1.06 0.09 20/564 0.61 0.34–1.11 0.11
Mutation position 0.44 0.04
Outside OCCR/BCCR 18/314 1.00 – 1.00 8/211 1.00 – 1.00
OCCR 46/608 1.26 0.73–2.17 0.41 32/526 1.61 0.74–3.52 0.23
BCCR 44/768 0.97 0.56–1.68 0.91 4/275 0.46 0.14–1.52 0.20
Model III
Family history
Without OC 87/1382 1.00 – 1.00 38/920 1.00 – 1.00
With OC 21/308 1.06 0.66–1.72 0.81 6/92 1.87 0.79–4.47 0.16
Mutation position 0.36 0.03
Outside OCCR/BCCR 18/314 1.00 – 1.00 8/211 1.00 – 1.00
OCCR 46/608 1.26 0.73–2.19 0.83 32/526 1.73 0.80–3.76 0.17
BCCR 44/768 0.94 0.54–1.63 0.17 4/275 0.49 0.15–1.62 0.24
OC ovarian cancer, HR hazard ratio, 95% CI 95% confidence interval, BC breast cancer, OCCR ovarian cancer cluster region, BCCR breast cancer
cluster region
a Three different multivariate models are presented
The association between cancer family history and ovarian cancer... 855
mutation carriers has been first reported >20 years ago [13,
14], it is based solely on epidemiological observations. The
biological mechanisms behind the epidemiological obser-
vations remain speculative.
The results of this study indicate that mutation position
explains part, but not all of the association between FH and
OC risk. Other genetic and environmental risk modifiers in
BRCA1/2 mutation carriers have been suggested [26].
Special attention has been recently given to genetic modi-
fiers identified either through candidate gene studies or
genome-wide association studies. Common variants related
to OC risk in the general population have been also asso-
ciated with OC risk in BRCA1/2 mutation carriers [27].
Moreover, loci that modify OC risk specifically in BRCA1/2
mutation carriers were also described [7, 28]. Several genes
may contribute to OC risk in a polygenic manner, and it has
been suggested that polygenic risk scores could be incor-
porated into risk prediction models in order to provide more
personalized OC risk estimations for BRCA1/2 mutation
carriers [29]. Furthermore, there might be other yet
unknown genes associated with higher risks of OC.
One limitation of this study is that it included only women
referred to family cancer clinics, and therefore might not be
representative of the entire population of BRCA1/2 mutation
carriers. However, the aim of this study was to provide
information regarding OC risk variation specifically for this
very population that is counseled in family cancer clinics.
Being a highly selected group, they may differ from popu-
lation based BRCA1/2mutation carriers. A second limitation
is that the number of OC cases was relatively small, espe-
cially on sensitivity analyses 2, likely due to the relatively
young mean age of this cohort (47.8 years), to the proportion
of women who had undergone RRSO (56.4%), a procedure
associated with up to 96% reduction of OC risks, or to other
competing causes of death [30]. The small number of OC
cases may have limited the power of the statistical analysis.
When interpreting the results it is also important to consider
that several models were performed and no statistical method
was applied to account for multiple testing. Furthermore, a
considerable proportion of women (32.4%) reported no
OCFH or BCFH. This may be due to limiting the FH infor-
mation to FDRs only: it is possible that these women have
SDRs with BC and/or OC. The families of the study parti-
cipants were relatively small (median of two female FDRs),
and may not be as informative as larger families. We did not
investigate the possible effect of family clustering in our
results, however, we do not expect this to have a major
impact on the observed associations, as the number of car-
riers per family was small [6, 18].
Strengths of this study are the large number of mutation
carriers included, and the high reliability of information on
cancer incidence and clinical characteristics of the included
women. Another strength is the use of sensitivity analyses
to evaluate possible bias on our results. Results of sensi-
tivity analyses were generally in line with those observed in
the main analyses, indicating that the effect of possible bias,
if present, is likely to be small.
In conclusion, a FH of BC tended to be associated with a
lower OC risk while a FH of OC tended to be associated
with higher OC risks in BRCA1/2 mutation carriers. This
observed trend was only partly explained by the mutation
position effect. Therefore, more research to identify (epi)
genetic factors explaining the variation in OC risk is nee-
ded, before a more individualized counseling can be
offered. Currently, RRSO is the only effective strategy to
reduce OC risk, which is generally offered to women with
an OC risk of >10%. Tailored risk estimation is paramount
for adequate counseling on the indication and timing of this
procedure. Although, considering the magnitude of the
trends observed in this study, we do not believe that specific
types of FH would be associated with lifetime risks low
enough to change the recommendation of RRSO for
BRCA1/2 mutation carriers, our observations could be taken
into account when discussing the timing of RRSO with
women considering to go through this procedure. Further-
more, the results from this study may be relevant for the
improvement of existing algorithms used for cancer risk
estimation in BRCA1/2 mutation carriers [31, 32].
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